RU2018145048A - Способы и композиции для лечения злокачественных опухолей, резистентных к ингибиторам пути non-erk марк - Google Patents
Способы и композиции для лечения злокачественных опухолей, резистентных к ингибиторам пути non-erk марк Download PDFInfo
- Publication number
- RU2018145048A RU2018145048A RU2018145048A RU2018145048A RU2018145048A RU 2018145048 A RU2018145048 A RU 2018145048A RU 2018145048 A RU2018145048 A RU 2018145048A RU 2018145048 A RU2018145048 A RU 2018145048A RU 2018145048 A RU2018145048 A RU 2018145048A
- Authority
- RU
- Russia
- Prior art keywords
- mutation
- erk
- mammal
- compositions
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G01N33/5758—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Способ лечения субъекта, имеющего неоперабельную или метастатическую меланому с мутацией BRAF600, включающий введение субъекту два раза в день 600 мг BVD-523 или его фармацевтически приемлемой соли.
2. Способ по п.1, где мутация представляет собой мутацию BRAFV600E.
3. Способ по п.1, где млекопитающее выбирают из группы, состоящей из человека, приматов, сельскохозяйственных животных и домашних животных.
4. Способ по п.1, где млекопитающее представляет собой человека.
5. Способ по п.1, где меланома имеет активность MAPK.
6. Композиция для лечения субъекта, имеющего неоперабельную или метастатическую меланому с мутацией BRAF600, где композиция содержит 600 мг BVD-523 или его фармацевтически приемлемой соли и, необязательно, фармацевтически приемлемый носитель, адъювант или наполнитель.
7. Композиция по п.6, где субъектом является млекопитающим.
8. Композиция по п.6, где млекопитающее выбирают из группы, состоящей из человека, приматов, сельскохозяйственных животных и домашних животных.
9. Композиция по п.6, где млекопитающее является человеком.
10. Композиция по п.6, где меланома имеет активность MAPK.
11. Композиция по п.6, в которой мутация представляет собой мутацию BRAFV600E.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919551P | 2013-12-20 | 2013-12-20 | |
| US15/161,137 | 2016-05-20 | ||
| US15/161,137 US20160317519A1 (en) | 2013-12-20 | 2016-05-20 | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| PCT/US2017/033843 WO2017201532A1 (en) | 2013-12-20 | 2017-05-22 | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018145048A true RU2018145048A (ru) | 2020-06-22 |
Family
ID=53403903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018145048A RU2018145048A (ru) | 2013-12-20 | 2017-05-22 | Способы и композиции для лечения злокачественных опухолей, резистентных к ингибиторам пути non-erk марк |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20160317519A1 (ru) |
| EP (2) | EP4653055A2 (ru) |
| JP (3) | JP7427212B2 (ru) |
| KR (2) | KR20230025941A (ru) |
| CN (2) | CN109475541A (ru) |
| AU (3) | AU2017267804B2 (ru) |
| BR (1) | BR112018073786A2 (ru) |
| CA (1) | CA3024703A1 (ru) |
| CL (1) | CL2018003282A1 (ru) |
| IL (2) | IL294056A (ru) |
| MX (2) | MX392121B (ru) |
| RU (1) | RU2018145048A (ru) |
| SG (1) | SG11201810287RA (ru) |
| WO (2) | WO2015095842A2 (ru) |
| ZA (2) | ZA201808480B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5869222B2 (ja) | 2008-01-04 | 2016-02-24 | インテリカイン， エルエルシー | 特定の化学的実体、組成物および方法 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| MX347708B (es) | 2011-01-10 | 2017-05-09 | Infinity Pharmaceuticals Inc | Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas. |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| WO2015095842A2 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| JP7061068B2 (ja) * | 2015-12-18 | 2022-04-27 | イグナイタ インコーポレイテッド | 癌治療のための併用薬 |
| WO2017180817A1 (en) * | 2016-04-15 | 2017-10-19 | Musc Foundation For Research Development | Treatment of septicemia and ards with erk inhibitors |
| EP3443114A1 (en) * | 2016-04-15 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| MX391135B (es) | 2016-06-24 | 2025-03-21 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| CN110799245B (zh) * | 2017-05-16 | 2022-08-09 | 生物医学谷探索股份有限公司 | 用于治疗具有非典型braf突变的癌症的组合物和方法 |
| ES2947411T3 (es) * | 2017-10-26 | 2023-08-08 | Xynomic Pharmaceuticals Inc | Sales cristalinas de un campo inhibidor de quinasa B-RAF |
| KR20210006365A (ko) * | 2018-04-09 | 2021-01-18 | 쥐원 쎄라퓨틱스, 인크. | 구동 종양원성 돌연변이를 갖는 암의 치료 |
| CN110656172A (zh) * | 2019-01-14 | 2020-01-07 | 南方医科大学珠江医院 | 一种预测小细胞肺癌对ep化疗方案敏感性的分子标志物及试剂盒 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4073102A4 (en) | 2019-12-12 | 2024-05-08 | Ting Therapeutics LLC | Compositions and methods for the prevention and treatment of hearing loss |
| KR102697384B1 (ko) * | 2022-01-13 | 2024-08-22 | 팔라디바이오텍 주식회사 | 리셉터 티로신 키나제 저해제를 탐색하는 방법 |
| CN115177622B (zh) * | 2022-07-19 | 2024-09-17 | 中南大学湘雅二医院 | 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0689610B1 (en) | 1993-03-19 | 2002-07-03 | Sequenom, Inc. | Dna sequencing by mass spectrometry via exonuclease degradation |
| US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| GB0320059D0 (en) | 2003-08-27 | 2003-10-01 | Solexa Ltd | A method of sequencing |
| ES2651439T3 (es) * | 2004-05-14 | 2018-01-26 | Vertex Pharmaceuticals Incorporated | Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| US20060228721A1 (en) | 2005-04-12 | 2006-10-12 | Leamon John H | Methods for determining sequence variants using ultra-deep sequencing |
| JP2008545670A (ja) * | 2005-05-27 | 2008-12-18 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 疾患を処置するためのジアリールウレア類を含む組合せ治療 |
| EP2347011B1 (en) | 2008-10-27 | 2017-01-18 | QIAGEN Gaithersburg, Inc. | Fast results hybrid capture assay and system |
| KR20120046018A (ko) | 2010-10-04 | 2012-05-09 | 삼성테크윈 주식회사 | 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출 |
| WO2012125848A2 (en) | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| KR20150038068A (ko) * | 2012-08-17 | 2015-04-08 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| HK1218506A1 (zh) * | 2013-02-11 | 2017-02-24 | 阿布拉科斯生物科学有限公司 | 治療黑素瘤的方法 |
| WO2014128235A1 (en) * | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Methods of treating cancer and preventing drug resistance |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| WO2015095834A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using erk1/2 and bcl-2 family inhibitors |
| WO2015095833A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
| CA3240745A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatment using combinations of erk and raf inhibitors |
| WO2016025649A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a dot1l inhibitor and related methods |
| CA3168216C (en) * | 2015-01-30 | 2025-11-18 | Biomed Valley Discoveries, Inc. | CRYSTALIN MALONATE C21H22Cl2N4O2 |
| EP4477222A3 (en) * | 2015-01-30 | 2025-02-26 | Biomed Valley Discoveries, Inc. | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt |
-
2014
- 2014-12-19 WO PCT/US2014/071749 patent/WO2015095842A2/en not_active Ceased
-
2016
- 2016-05-20 US US15/161,137 patent/US20160317519A1/en not_active Abandoned
-
2017
- 2017-05-22 AU AU2017267804A patent/AU2017267804B2/en active Active
- 2017-05-22 WO PCT/US2017/033843 patent/WO2017201532A1/en not_active Ceased
- 2017-05-22 CA CA3024703A patent/CA3024703A1/en active Pending
- 2017-05-22 MX MX2018014231A patent/MX392121B/es unknown
- 2017-05-22 RU RU2018145048A patent/RU2018145048A/ru not_active Application Discontinuation
- 2017-05-22 EP EP25207698.9A patent/EP4653055A2/en active Pending
- 2017-05-22 KR KR1020237004648A patent/KR20230025941A/ko not_active Ceased
- 2017-05-22 JP JP2018560887A patent/JP7427212B2/ja active Active
- 2017-05-22 US US16/302,955 patent/US11246859B2/en active Active
- 2017-05-22 IL IL294056A patent/IL294056A/en unknown
- 2017-05-22 KR KR1020187037187A patent/KR20190009804A/ko not_active Ceased
- 2017-05-22 BR BR112018073786-0A patent/BR112018073786A2/pt not_active Application Discontinuation
- 2017-05-22 SG SG11201810287RA patent/SG11201810287RA/en unknown
- 2017-05-22 IL IL263108A patent/IL263108B/en unknown
- 2017-05-22 EP EP17800334.9A patent/EP3458056B1/en active Active
- 2017-05-22 CN CN201780044255.XA patent/CN109475541A/zh active Pending
- 2017-05-22 CN CN202510671199.9A patent/CN120501744A/zh active Pending
- 2017-10-30 US US15/797,593 patent/US10881646B2/en active Active
-
2018
- 2018-11-19 CL CL2018003282A patent/CL2018003282A1/es unknown
- 2018-11-20 MX MX2022005473A patent/MX2022005473A/es unknown
- 2018-12-14 ZA ZA2018/08480A patent/ZA201808480B/en unknown
-
2020
- 2020-10-23 US US17/078,255 patent/US20210038587A1/en active Pending
- 2020-12-11 ZA ZA2020/07734A patent/ZA202007734B/en unknown
-
2021
- 2021-12-23 US US17/561,076 patent/US20220117950A1/en active Pending
- 2021-12-28 JP JP2021214205A patent/JP2022034068A/ja not_active Withdrawn
-
2023
- 2023-07-11 AU AU2023204587A patent/AU2023204587B2/en active Active
-
2024
- 2024-07-05 JP JP2024108968A patent/JP2024133638A/ja active Pending
-
2025
- 2025-06-19 AU AU2025204585A patent/AU2025204585A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018145048A (ru) | Способы и композиции для лечения злокачественных опухолей, резистентных к ингибиторам пути non-erk марк | |
| EA201591483A1 (ru) | Производные имидазо[4,5-с]пиридина и пирроло[2,3-с]пиридина в качестве ингибиторов ssao | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| EA201401062A1 (ru) | Бициклические пиразиноновые производные | |
| MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| EA201401212A1 (ru) | Производные пирролотриазинона | |
| UA122324C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| EA201270373A1 (ru) | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| JP2017528475A5 (ru) | ||
| EA201491008A1 (ru) | Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита | |
| JP2019519519A5 (ru) | ||
| EA201890768A3 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| EA201500484A1 (ru) | Лечение или профилактика сердечно-сосудистых явлений с использованием производного колхицина | |
| EA201690989A1 (ru) | Ингибиторы syk | |
| JP2016506935A5 (ru) | ||
| EA201301301A1 (ru) | Производные тиазола | |
| EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
| EA201100136A1 (ru) | 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака | |
| EP3133074A3 (de) | 7-azaindolderivate | |
| SA519401970B1 (ar) | مثبطات حلقية غير متجانسة لناقل مونوكربوكسيلات 4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200525 |